Byron S. Kalogerou is the founder of the Firm’s Life Science Industry Group and the senior attorney in the Boston Corporate Practice. He focuses his practice on domestic and cross-border mergers and acquisitions, finance, and joint ventures and alliances. He has substantial on-the-ground experience structuring mergers, acquisitions, divestitures and joint ventures on six continents. Byron has extensive industry background in the life science, industrial and manufacturing sectors. He also acts as outside general counsel to a number of companies.
Byron spent 17 years in-house, where he served in various general counsel roles at Tyco International, including as general counsel of its fire and security and telecom businesses and as general counsel of its international legal department, a function he created. Byron led many of Tyco’s largest acquisitions, including the $12 billion acquisition of AMP Inc. and the $850 million purchase of AT&T Submarine Systems, and handled hundreds of middle-market deals around the globe. Byron also handled Tyco’s initial foray into medical devices and led many of the deals that formed Covidien, now part of Medtronic.
Byron returned to law firm life 14 years ago with a desire to bring his keen sense of the “voice of the customer” to drive predictability, value and efficiency into the deal process. Byron is a pioneer in the use of legal project management and co-chair of the American Bar Association (ABA) Committee on Mergers and Acquisitions’ Task Force on Legal Project Management. He is co-editor of the ABA Guidebook “Using Legal Project Management in Merger & Acquisition Transactions”, now in its second edition. Byron also created the first-of-its-kind web-based collaborative deal management portal, which the Firm adopted and embraced as the M&A Gateway. He is also one of the Firm’s primary contacts with the Association of Corporate Counsel.
Byron is a member of our legal cannabis industry group. Our Cannabis Industry group is a multidisciplinary team of lawyers providing clients with regulatory, litigation, intellectual property, trade and tax services with respect to their investments and participation in the cannabis industry, all subject to the Firm’s obligations under federal and state laws and bar licensure rules.
Represented Straumann AG, a global leader in tooth replacement solutions, in its acquisition of ClearCorrect, LLC, a leading manufacturer of clear aligners, for $150 million.
Represented Anvil, LLC, a leading North American manufacturer and supplier of products that connect, hang and support piping systems, in various acquisitions, including Flexhead Industries, Sprinkflex, Basic-PSA and Megawatt Machine.
Represented Take 5 Media Group, a leading consumer information aggregation and advertising company, in the sale of its business to Advantage Solutions, a leading North American provider of business solutions to consumer goods manufacturers and retailers.
Represented Covidien in its first equity acquisition in China of Changzhou Kangdi Medical Stapler Co., Ltd., a manufacturer of surgical stapler products
Represented Rogers Corporation (NYSE: ROG), a global technology leader in specialty materials and components, in its $157 million acquisition of Arlon, a global provider of high-frequency circuit materials and engineered silicones
Represented Dimension Data, a global infrastructure solution (IS) provider and an NTT Group company, in its acquisition of Nexus IS, Inc., a $471 million information technology (IT) solutions provider
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.